Who Protects You in a Clinical Trial? Meet the IRB
Before any clinical trial can start, an independent group of experts and community members must approve it. That group is the institutional review board, usually called an IRB, and it is the first line of protection for research participants. An IRB is an independent committee that reviews, approves, and monitors research with human subjects. It is not part of the research team. Its sole mission is to protect the rights, safety, and well-being of the people in the study.
Why IRBs exist
IRBs exist because of scandal. The Tuskegee syphilis study, in which hundreds of Black men were denied treatment for decades without meaningful consent, helped push Congress to pass the National Research Act of 1974, which mandated IRBs for federally funded research. The Belmont Report of 1979 supplied the ethical framework, and the Common Rule, 45 CFR 46, defines how IRBs operate today. These protections did not stop at US borders, either: the EU's clinical trials framework gives the same gatekeeping job to ethics committees in every member state.
Who sits on an IRB
Federal regulations spell out the membership. Under 21 CFR 56.107, an IRB must have at least five members with varying backgrounds. That means scientific members, doctors and researchers who understand the protocol. It also means non-scientific members: lawyers, clergy, and community advocates. And at least one member must have no connection to the institution running the study, so the participant's perspective is represented rather than the institution's convenience.
What the IRB actually reviews
Every detail of a trial gets examined. Is the consent form written in clear language? Are the risks minimized? Is the science sound? Is the recruitment plan fair? How is privacy protected? Are the investigators qualified? The NIH human subjects policy pages describe the same review expectations for the research it funds.
Not every study needs the full board. There are three levels of review:
- Full board review is for studies that pose more than minimal risk. The whole committee meets and votes.
- Expedited review is for minimal-risk studies and is done by one or two members.
- Exempt covers very low risk work like anonymous surveys.
The IRB can make three decisions. It can approve the study, require modifications before approval, or disapprove it entirely. Most full-board reviews take four to eight weeks.
Oversight does not stop at approval
Approval is a beginning, not an end. Studies that went through full-board review need continuing review at least once a year under the Common Rule. Serious adverse events must be reported quickly, and protocol amendments must be approved before they are implemented.
The IRB is not the only safety body in a trial, and the two are often confused. The IRB reviews before the study starts. A data and safety monitoring board (DSMB) reviews during the study, sees unblinded data, and can stop a trial early if a treatment is clearly working or clearly harmful. The FDA's guidance on data monitoring committees explains the DSMB role in detail. The two bodies are complementary: one guards the door, the other watches the road.
IRBs around the world
Every country has its own version. The EU runs on ethics committees. The UK uses research ethics committees under the Health Research Authority. Japan has certified review boards. The structure differs; the mission does not. Protect the human subjects.
Criticisms and changes
IRBs have real problems. They can be slow. Different IRBs reach different conclusions on the same protocol. Their mission has expanded far beyond what the 1974 Act imagined, and smaller institutions struggle to staff them. The system is adapting. Artificial intelligence in research raises new ethics questions, and decentralized trials challenge site-based oversight. One concrete change: for NIH-funded multi-site studies, a single IRB is now required instead of every site running its own review. The idea is to cut duplication without cutting protection.
The bottom line
Participants can contact the IRB directly. The phone number and email are on the consent form. If you feel pressured, or mistreated, or simply misled, the IRB can intervene. It works for you. Every trial that starts with the question "are we protecting the participants?" starts with the answer the IRB provides.
This article is based on the Clarity Clinical Solutions video "Who Protects You in a Clinical Trial? Meet the IRB." Watch it here: Who Protects You in a Clinical Trial? Meet the IRB
References
- Clarity Clinical Solutions — "Who Protects You in a Clinical Trial? Meet the IRB" (video). https://www.youtube.com/watch?v=bIjicaYtFJU
- eCFR 45 CFR 46 — the Common Rule: IRB review levels, membership, and continuing review requirements. https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46
- eCFR 21 CFR 56 — the FDA's IRB regulations, including membership composition. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-56
- FDA guidance — establishment and operation of clinical trial data monitoring committees. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishment-and-operation-clinical-trial-data-monitoring-committees
- NIH policy — human subjects protections and the single IRB requirement for multi-site research. https://grants.nih.gov/policy/humansubjects.htm and https://grants.nih.gov/policy/humansubjects/single-irb-policy-multi-site-research.htm
- EMA — clinical trials in human medicines: how ethics committees fit into European regulation. https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials-human-medicines